3/6
12:35 pm
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Medium
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
3/6
03:21 am
bmea
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function [Yahoo! Finan
Medium
Report
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function [Yahoo! Finan
3/6
03:04 am
bmea
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Medium
Report
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
3/1
04:38 pm
bmea
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/1
04:16 pm
bmea
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/27
02:08 am
bmea
Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research [Seeking Alpha]
High
Report
Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research [Seeking Alpha]
2/6
07:14 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $55.00 price target on the stock.
Medium
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $55.00 price target on the stock.
1/16
06:24 pm
bmea
‘A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks [CNBC]
Medium
Report
‘A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks [CNBC]
1/9
11:13 am
bmea
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/9
11:02 am
bmea
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Low
Report
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
1/8
09:00 am
bmea
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
Medium
Report
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
1/2
04:08 pm
bmea
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/2
04:05 pm
bmea
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Low
Report
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference